NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 216 filers reported holding NEKTAR THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $19 | -68.3% | 26,678 | 0.0% | 0.00% | – |
| Q4 2022 | $60 | -99.9% | 26,678 | 0.0% | 0.00% | – |
| Q3 2022 | $85,000 | -15.8% | 26,678 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $101,000 | -29.9% | 26,678 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $144,000 | -60.0% | 26,678 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $360,000 | -24.8% | 26,678 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $479,000 | +4.6% | 26,678 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $458,000 | -14.2% | 26,678 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $534,000 | +17.6% | 26,678 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $454,000 | +2.5% | 26,678 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $443,000 | -28.3% | 26,678 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $618,000 | +29.8% | 26,678 | 0.0% | 0.00% | +33.3% |
| Q1 2020 | $476,000 | -8.3% | 26,678 | +11.0% | 0.00% | 0.0% |
| Q4 2019 | $519,000 | +18.5% | 24,030 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $438,000 | -48.8% | 24,030 | 0.0% | 0.00% | -40.0% |
| Q2 2019 | $855,000 | +5.9% | 24,030 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $807,000 | -17.4% | 24,030 | -19.2% | 0.01% | -28.6% |
| Q4 2018 | $977,000 | -46.2% | 29,729 | -0.2% | 0.01% | -36.4% |
| Q3 2018 | $1,816,000 | +24.7% | 29,795 | -0.1% | 0.01% | +22.2% |
| Q2 2018 | $1,456,000 | -43.0% | 29,825 | +24.1% | 0.01% | -47.1% |
| Q1 2018 | $2,553,000 | -88.8% | 24,030 | -93.7% | 0.02% | -88.3% |
| Q4 2017 | $22,789,000 | +3155.6% | 381,590 | +1207.8% | 0.14% | +2800.0% |
| Q3 2017 | $700,000 | +16.5% | 29,177 | -5.1% | 0.01% | +25.0% |
| Q2 2017 | $601,000 | -16.8% | 30,748 | 0.0% | 0.00% | -20.0% |
| Q1 2017 | $722,000 | +91.5% | 30,748 | 0.0% | 0.01% | +66.7% |
| Q4 2016 | $377,000 | -28.6% | 30,748 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $528,000 | +11.4% | 30,748 | -7.6% | 0.00% | 0.0% |
| Q2 2016 | $474,000 | +3.5% | 33,291 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $458,000 | -23.9% | 33,291 | -6.9% | 0.00% | -20.0% |
| Q4 2015 | $602,000 | +53.6% | 35,745 | 0.0% | 0.01% | +66.7% |
| Q3 2015 | $392,000 | -12.9% | 35,745 | -0.6% | 0.00% | -25.0% |
| Q2 2015 | $450,000 | +13.6% | 35,958 | 0.0% | 0.00% | +33.3% |
| Q1 2015 | $396,000 | -35.0% | 35,958 | -8.5% | 0.00% | -40.0% |
| Q4 2014 | $609,000 | +28.5% | 39,308 | 0.0% | 0.01% | +25.0% |
| Q3 2014 | $474,000 | -6.0% | 39,308 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $504,000 | +5.9% | 39,308 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $476,000 | +6.7% | 39,308 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $446,000 | +8.5% | 39,308 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $411,000 | -9.5% | 39,308 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $454,000 | – | 39,308 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |